Furosemide + Matched Hydration Cuts Contrast-Induced AKI

This article originally appeared here.
Share this content:
Furosemide + Matched Hydration Cuts Contrast-Induced AKI
Furosemide + Matched Hydration Cuts Contrast-Induced AKI

TUESDAY, Feb. 21, 2017 (HealthDay News) -- For high-risk patients undergoing percutaneous coronary intervention or transcatheter aortic valve replacement, furosemide with matched hydration via the RenalGuard system may reduce the incidence of contrast-induced acute kidney injury (CI-AKI), according to a meta-analysis published in the Feb. 27 issue of JACC: Cardiovascular Interventions.

Alessandro Putzu, M.D., from the Cardiocentro Ticino in Lugano, Switzerland, and colleagues conducted a meta-analysis to examine whether furosemide with matched hydration using the RenalGuard System correlated with reduced CI-AKI in patients undergoing interventional procedures. Four trials published from 2011 to 2016 with 698 patients undergoing percutaneous coronary procedures and transcatheter aortic valve replacement were included in the analysis.

The researchers found that, compared with control treatment, RenalGuard therapy correlated with significantly reduced incidence of CI-AKI (7.76 versus 21.43 percent; odds ratio, 0.31), as well as a reduced need for renal replacement therapy (0.58 versus 3.45 percent; odds ratio, 0.19). There were no major adverse events among patients undergoing RenalGuard therapy.

"Further independent high-quality randomized trials should elucidate the effectiveness and safety of this prophylactic intervention in interventional cardiology," the authors write.

Abstract
Full Text
Editorial

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Even Overdose Doesn't Stop Opioid Prescribing

Even Overdose Doesn't Stop Opioid Prescribing

Few receive medication-assisted treatment after hospital discharge, researchers find

NT-ProBNP-Guided Treatment No Benefit in High-Risk HFrEF

NT-ProBNP-Guided Treatment No Benefit in High-Risk HFrEF

No improvement in clinical outcomes versus usual care in heart failure and reduced ejection fraction

Oral Corticosteroids No Benefit for LRI in Non-Asthmatic Adults

Oral Corticosteroids No Benefit for LRI in Non-Asthmatic ...

No decrease in cough duration, severity for adults without asthma with lower respiratory tract symptom

is free, fast, and customized just for you!

Already a member?

Sign In Now »